[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Royal United Hospitals Bath NHS Foundation Trust\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":173},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,74,94,123,154],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100625081","a-study-of-clinical-and-immune-responses-to-sequential-biologic-therapies-in-psoriatic-arthritis-100625081",false,"NCT07417995","A Study of Clinical and Immune Responses to Sequential Biologic Therapies in Psoriatic Arthritis","STRIDE-PsA: A Study of Treatment Response and Immunogenicity in Sequential Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drug (b\u002FtsDMARD) Exposure in Psoriatic Arthritis","STRIDE-PsA","Inclusion Criteria:\n\n* Age ≥18 years\n* Clinical diagnosis of PsA meeting CASPAR criteria\n* Starting a new b\u002FtsDMARD, irrespective of line of therapy\n\nExclusion Criteria:\n\n* Switching b\u002FtsDMARD therapy for psoriasis or spondyloarthritis alone, without active psoriatic arthritis.\n* Previous treatment with the same b\u002FtsDMARD being started at baseline.\n* Inability or unwillingness to provide informed consent.","ALL","18 Years",{"count":20,"type":21},400,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to evaluate how well advanced therapies work in adults with psoriatic arthritis (PsA) who are starting a biologic or targeted synthetic disease-modifying antirheumatic drug (b\u002FtsDMARD) as part of routine care.\n\nThe main questions are:\n\n* Do treatment responses differ according to the number of previous advanced therapies?\n* Can anti-drug antibodies (ADAs) or blood drug levels help predict treatment effectiveness?\n\nResearchers will compare participants receiving earlier-line versus later-line advanced therapies to assess differences in treatment response and antibody development.\n\nParticipants will allow collection of routine clinical assessment data, complete questionnaires on symptoms and quality of life, and provide blood samples before treatment and at 12 weeks.",[25],"Psoriasis Arthritis",[27,28,29,30],"Anti-drug antibody","Biologic therapies","Immunogenicity","Targeted Synthetic DMARDs","NOT_YET_RECRUITING","2026-05-12",{"date":34,"type":35},"2026-05-13","ACTUAL",{"date":37,"type":21},"2026-06",{"date":39,"type":21},"2027-06",{"name":41,"class":42},"Royal United Hospitals Bath NHS Foundation Trust","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":43},"100607381","sequential-treatment-of-psoriasis-with-biologics-100607381","NCT07187817","SEquential Treatment of PSoriasis With Biologics","STEPS","Inclusion Criteria:\n\n* Diagnosis of chronic plaque psoriasis by a Dermatology consultant\n* Prior treatment with biologic or targeted synthetic treatment (1 to 10 lines) for psoriasis in the United Kingdom\n\nExclusion Criteria:\n\n* Diagnosis of other forms of psoriasis for example generalised pustular psoriasis",{"count":52,"type":21},366,"Psoriasis is a common skin condition that leads to patches of scaled skin which can be inflamed, sore and itchy. It can affect any area of skin on the body, as well as nails, and can be widespread and severe. Over the past 20 years, many new treatments have been developed and approved for severe psoriasis. Most of these newer treatments are given by injection and, as a group, are known as biologics. Many people respond well to biologics and have a meaningful improvement in their condition. There is a smaller proportion of people who do not respond well, or develop side effects, and so must switch drugs to try and improve their condition. In some cases, people need multiple lines of biologic treatment. Currently very little is understood about how well people respond when they are treated with three or more biologics in a row, as very few trials have been done in these cases.\n\nThis study aims to use data from people who have already been treated with biologics by their Dermatology teams in the NHS and use the information obtained during their normal clinic appointments to investigate this question. The investigators will assess how well people respond to each line of biologic drug (1st to 10th). They will look at whether people respond as well or less well over time, the more biologics they have. People can be included in the research if they are 18 or over and have been treated with a biologic for psoriasis in participating hospitals in the NHS in England. In this study the investigators are assessing data from events that have previously happened, and so no extra visits are required",[55],"Psoriasis",[57,58,59,60,61,62,63,64],"biologic","bdmard","tsdmard","biological agent","3rd line","4th line","switch","cycle","RECRUITING","2026-02-12",{"date":68,"type":35},"2026-02-13",{"date":70,"type":35},"2025-10-14",{"date":72,"type":21},"2026-05-05",{"name":41,"class":42},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":43},"100560707","respiratory-parameters-using-advanced-airways-during-in-hospital-cardiac-arrest-100560707","NCT06580652","Respiratory Parameters Using Advanced Airways During In-hospital Cardiac Arrest","Measurement of Tidal Volumes Achieved With Tracheal Tubes and Laryngeal Mask Airways During in Hospital Cardiac Arrest.","Inclusion Criteria:\n\n* As per AIRWAYS-3 trial:\n* In-hospital cardiac arrest, attended by the hospital cardiac arrest team in response to a cardiac arrest call (2222 or equivalent), and when a clinician permitted to undertake both tracheal intubation and supraglottic airway placement (so that either intervention can be delivered) is present\n* Undergoing resuscitation and requiring advanced airway management in the opinion of the trained clinician responsible for randomisation\n\nExclusion Criteria:\n\n* As per AIRWAYS-3 trial\n* Patients who have a cardiac arrest outside hospital and who are transported to the hospital in ongoing cardiac arrest\n* People who are not a hospital inpatient (e.g. visitor, relative, staff or outpatient)\n* Patients who are already tracheally intubated at the time of eligibility assessment\n* Patients known to be pregnant\n* Patients with a functioning tracheostomy",{"count":82,"type":21},30,"The investigators aim to investigate the real life volumes of air delivered to the lungs when rescuers deliver these breaths by hand as part of resuscitation attempts during cardiac arrest. The study will compare the volumes achieved using different devices which are routinely used to provided an airway during routine cardiac arrest care. Volumes will be measured using a small non intrusive device which sits in the airway circuit and measures flow of air in real time. The patients chosen for this study will be those already recruited to an ongoing trial (AIRWAYS-3) assessing the outcomes for patients suffering in hospital cardiac arrest based on airway device used.",[85],"Cardiac Arrest","2025-11-20",{"date":88,"type":35},"2025-11-21",{"date":90,"type":35},"2024-08-28",{"date":92,"type":21},"2026-08-01",{"name":41,"class":42},{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":102,"minAge":18,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":105,"phases":106,"briefSummary":108,"conditions":109,"keywords":113,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":43},"100602943","virtual-reality-in-elective-caesarean-births-study-vrec-100602943","NCT07130084","Virtual Reality in Elective Caesarean Births Study (VREC)","Virtual Reality in Elective Caesarean Births Study (VREC)- A Feasibility Study for a Virtual-reality Based Tool to Improve Patient Reported Outcomes Following Elective Caesarean Section.","VREC","Inclusion Criteria:\n\n* Have had the decision for elective LSCS by 38 weeks gestation.\n* Has never had an emergency or elective section previously\n* Have a procedure planned and performed as a category 4 LSCS (an elective LSCS booked at a time that suits both the woman and obstetric team)\n* Have use of an android or iOS operating system smartphone or tablet device.\n* Have access to the internet.\n* Have an active email address.\n* Have capacity to consent to participate in the study.\n\nExclusion Criteria:\n\n* Patient \\\u003C18 years of age\n* Patient refusal\n* Patients who have had an emergency or elective LSCS previously.\n* Patients with a history of anxiety disorders\n* Patients with medical or obstetric co-morbidities requiring pre-determined admission to maternity HDU care\n* Congenital structural abnormalities requiring pre-determined admission to NICU\n* Patients where spinal anaesthesia is contra-indicated\n* Women who have English of an insufficient standard to comprehend the consent and assessment process\n* Prisoners","FEMALE",{"count":104,"type":21},40,"INTERVENTIONAL",[107],"NA","This study will establish the safety of a known intervention in a novel setting. It will assess how maternal anxiety during the peri-operative period of an elective cesarean section (eCS) is affected by the introduction of a virtual reality (VR) tool. A cesarean section is the most common operation performed in the world. Indeed, locally, we perform approximately 450 eCS annually, equating to 10% of all births. High maternal anxiety in the peri-operative period is well recognised. Although anxiety is considered to be an emotional response it has many physiological consequences which can confer significant morbidity. These include an increased pain perception (with higher analgesic requirement), increased length of hospital stay and a higher risk of infection. Providing high-quality pre-operative information to help patients reduce their anxiety has been used in other medical fields. The use of VR to deliver this information to paediatric populations has been shown to be particularly effective. VR has had limited scope outside of this population and we wish to change this.\n\nWomen booked for an eCS at the Royal United Hospital (RUH) will be eligible to participate. A bespoke VR tool (a video of a woman's journey through the process of an elective section at the RUH) will be shown to one group of women prior to eCS whilst another group will receive the standard preoperative information.\n\nA series of quantitative and qualitative data points will be collected across both groups assessing their anxiety and satisfaction with the birthing process throughout the peri-operative period. The two groups will then be compared.\n\nRecruitment will occur prior to the birth during scheduled appointments with the Midwifery team. If proven to be a safe intervention, we hope to run a larger study aiming to determine the efficacy and role of VR in improving maternal outcomes in cesarean births.",[110,111,112],"Anxiety","Pregnancy","Pain",[114],"Virtual reality","2025-08-12",{"date":117,"type":35},"2025-08-19",{"date":119,"type":35},"2024-10-14",{"date":121,"type":21},"2025-09-01",{"name":41,"class":42},{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":105,"phases":131,"briefSummary":132,"conditions":133,"keywords":137,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":153},"100568489","microvascular-coronary-rehabilitation-for-improving-treatment---feasibility-study-100568489","NCT06681896","Microvascular Coronary Rehabilitation For Improving Treatment - Feasibility Study","MICROFIT","Inclusion Criteria:\n\n* Age ≥18\n* Angina or angina equivalent symptoms\n* Unobstructed coronary arteries at the time of coronary angiogram. This will be defined as plaque causing \\\u003C40% epicardial vessel stenosis or 40-90% with a fractional flow reserve (FFR) ≥0.8\n* Evidence of microvascular dysfunction on ICA (CFR \\\u003C2.5 and\u002For AchFR \\\u003C1.5)\n\nExclusion Criteria:\n\n* New York Heart Association class III\u002FIV heart failure\n* Severe left ventricular impairment (ejection fraction≤35%)\n* Severe heart valve disease\n* Significant cardiomyopathy (as assessed by a cardiologist)\n* Severe hypertension (defined as blood pressure \\>180\u002F120mmHg (despite three anti-hypertensive agents)\n* Uncontrolled arrhythmia\n* A history of aortic dissection, recent (\\\u003C6 months) acute pulmonary embolus, deep vein thrombosis, stroke or transient ischaemic attack, severe autonomic or peripheral neuropathy, acute systemic illness or fever, severe acute or chronic renal failure, severe pulmonary fibrosis or interstitial lung disease (in line with other trials investigating HIIT exercise)\n* Pregnancy or breastfeeding (at any point during the study. Patients becoming pregnant during the study will be asked to withdraw due to additional radiation exposure and risks from HIIT)\n* Physical inability to participate in exercise\n* Significant claustrophobia or metallic implants which would limit MRI imaging\n* Intolerance to regadenoson testing (high degree atrioventricular block, severe asthma or airways disease)\n* Current participation in another intervention-based trial\n* Inability to fully understand the verbal and written descriptions of the study and instructions provided during the study duration.",{"count":104,"type":21},[107],"The goal of this clinical trial is to assess the feasibility of undertaking a randomized controlled trial assessing the impact of a personalised, intense cardiac rehabilitation programme involving high intensity interval exercise (HIIT) and dietary advice (termed MICROFIT) on symptom burden in patients with microvascular coronary dysfunction.\n\nThe main questions it aims to answer are:\n\n1. Feasibility of undertaking randomised controlled trial of MICROFIT in patients with coronary microvascular dysfunction (recruitment rates, retention and adherence, acceptability of MICROFIT and participants' and practitioners' experiences of trial participation)\n2. Preliminary data on the effect that MICROFIT has on angina symptoms in patients with microvascular coronary dysfunction, as measured by Seattle Angina Questionnaire\n3. Preliminary data on the fidelity and clinical efficacy of MICROFIT\n\nParticipants will be randomized to either MICROFIT + Usual Care, or Usual Care group.\n\nParticipants in both arms of the trial will:\n\n* Undergo a series of investigations, including cardiopulmonary exercise test (CPET), dual xray absorptiometry (DEXA), echocardiogram, cardiac MRI scan, blood tests, at the start of the trial and again after 6 months\n* Measure their living activity by using an activity tracker (GeneActiv) as well as a photographic diet diary for a week at the start of the trial and again after 6 months\n* Complete a series of questionnaires to assess angina symptom burden, mental health and quality of life, at the start of the trial and again after 6 months.\n\nParticipants in the intervention arm of the study will:\n\n1. Undergo MICROFIT intervention. MICROFIT includes a combination of exercise and diet management sessions over 24 weeks. It involves:\n\n   * 1:1 high-intensity interval training ('HIIT') sessions with a personal trainer and guidance on exercise sessions to be performed at home\n   * 1:1 sessions with a dietician to support them with improvements in diet.\n2. Visit clinic on two additional occassions during the trial to discuss their progress with a cardiologist\n3. Undergo an interview at the end of the study to discuss their experiences of participation in the study\n4. Receive a debrief on their investigation results and progress made at the end of their study\n\nParticipants in the Usual Care arm of the study will:\n\n1. Receive standard Usual Care advice regarding lifestyle changes and targeted medical therapy offered to patients with coronary microvascular dysfunction.\n2. Receive a debrief on their investigation results and progress made at the end of their study\n3. Undergo a 'taster' session with the personal trainer to discover what the intervention involves.",[134,135,136],"Microvascular Coronary Dysfunction","Microvascular Angina","Coronary Microvascular Dysfunction (CMD)",[138,139,140,141,142,143,144],"coronary microvascular dysfunction","HIIT","high intensity interval exercise training","exercise training","dietary rehabilitation","lifestyle advice","microvascular angina","2025-06-17",{"date":147,"type":35},"2025-06-18",{"date":149,"type":35},"2024-11-12",{"date":151,"type":21},"2027-01-01",{"name":41,"class":42},2,{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":166,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":172},"100545767","developing-the-probability-algorithm-for-pulmonary-hypertension-echocardiography-100545767","NCT06386185","Developing the Probability Algorithm for Pulmonary Hypertension Echocardiography","DRAPE","Inclusion Criteria:\n\n* Patients 18+ who have undergone TTE, ECG and RHC as part of their clinical care\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years old\n* Known or suspected congenital heart disease\n* Patient has opted-out of allowing their data to be used for research and planning (via the national data opt-out choice in England, or equivalent data protection scheme in Scotland)",{"count":162,"type":21},2500,"The goal of this observational study is to assess the efficacy that the addition of novel markers cardiac function, particularly of right ventricular (RV) function in echocardiography, and ECG have in detecting pulmonary hypertension.\n\nThe main questions it aims to answer are:\n\nCan novel markers in ECG and echocardiography suggest the presence of PH? Can existing screening guidelines be improved with the addition of these markers?",[165],"Pulmonary Hypertension",{"date":147,"type":35},{"date":168,"type":35},"2024-09-06",{"date":170,"type":21},"2026-12-01",{"name":41,"class":42},5,""]